The 3.2 Å structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain.
Ian W SmithAnne E d'AquinoChristopher W CoyleAndrew FedanovErnest T ParkerGabriela DenningHarold Trent SpencerPete LollarChristopher B DoeringPaul Clinton SpiegelPublished in: Journal of thrombosis and haemostasis : JTH (2019)
These improved structures yield a more confident model for next-generation engineering efforts to develop FVIII therapeutics with longer half-lives, higher expression levels, and lower immunogenicity.